Cardiol Therapeutics’ Three-Month Net Loss Widens 34% to CAD 13.32 Million

• Cardiol Therapeutics' three-month net loss widened 34% year-over-year to CAD 13.32 million for the period ended September 30, 2026.
• Net cash used in operating activities fell 12% year-over-year to CAD 16.47 million for the nine months ended September 30, 2026.
• Cash and cash equivalents rose 36% from December 31, 2025, to CAD 29.23 million at September 30, 2026.
• Subsequent to September 30, 2026, the company raised USD 4.55 million in gross proceeds under its 2026 at-the-market offering program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-126269), on November 12, 2026, and is solely responsible for the information contained therein.